Healwell AI’s Revenue Rocket Doesn’t Lift the Stock – Yet

Healwell AI posts 316% revenue surge to CAD 33.2M, driven by Orion acquisition, yet shares trade 40% lower over 12 months. Adjusted EBITDA turns positive.

Healwell AI just posted a 316% revenue surge to CAD 33.2 million in its fiscal first quarter, yet its shares are stuck in a deep rut. On the Toronto Stock Exchange the stock clawed back to CAD 0.88 after dipping to CAD 0.78 intraweek, while in Frankfurt it closed Friday at EUR 0.53, down 1.48% on the day. Over twelve months the equity has shed roughly 40%, and at current levels it trades 17% below the 200-day moving average of EUR 0.64. The disconnect between operating momentum and market reception is stark.

The headline growth owes largely to last year’s acquisition of Orion Health. Healthcare software revenue exploded 439% to CAD 30.6 million from CAD 5.7 million a year earlier. The smaller AI and data science segment grew at a more modest 13% clip, reaching CAD 2.6 million. Profitability is also moving in the right direction: adjusted EBITDA turned positive at CAD 0.7 million, reversing a CAD 2.3 million loss in the prior-year quarter. Gross profit reached CAD 19.5 million, yielding a 59% margin, while the IFRS net loss from continuing operations narrowed to CAD 6.8 million from CAD 14.1 million. The company ended March with CAD 21.9 million in cash, up from CAD 18.6 million at year-end.

Beyond the numbers, Healwell is racing to close a strategic asset sale by the end of May. The planned disposal of its HEAL Access Canada subsidiary to AI Maverick Intel involves 20 million exchange shares and a secured seller note of US$5 million, contingent on the buyer having positive net working capital of the same amount. On the commercial front, the company has landed its first artificial-intelligence contract with a large state health system in the Middle East and a multi-million-dollar US deal in health information exchange. Product enhancements include embedded AI features such as Smart Search, Smart Summary and Smart ID within the Orion platform, while the Amadeus AI product is slated for a North American launch in the first half of 2026. On the evidence front, Healwell’s DARWEN AI platform now boasts 47 peer-reviewed publications, with three additional conference acceptances already logged this year across therapeutic areas ranging from inflammatory bowel disease to suicidal ideation in plaque psoriasis.

Wall Street analysts have tempered their enthusiasm, though the implied upside remains enormous. The average price target was trimmed by CAD 0.50 to CAD 3.10, reflecting adjusted assumptions on revenue growth, margins, discount rates and valuation multiples. The consensus loss per share for fiscal 2026 was also reduced, to CAD 0.07 from CAD 0.106, while the revenue forecast held steady at CAD 136.4 million. Management itself has set ambitious internal targets: AI-related revenue growth of roughly 50% for the full year and a 10% adjusted EBITDA margin by year-end. All eyes now turn to the annual general meeting scheduled for June 25, 2026, where shareholders will vote on board composition and the company can showcase its next steps. Until the asset sale clears and the market sees sustained evidence of margin expansion, Healwell AI’s stock may continue to trade at odds with its operational turnaround.